This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Follicular lymphoma여포성 림프종 (여포성림프종)

Classification codes C82 (KCD-8 / ICD-10)
Special Copayment Reduction V193 · 5 years from the cancer patient registration date · 5% copayment
Synonyms Follicular non-Hodgkin lymphoma, nodular lymphoma (obsolete term), FL grade 1/2/3A/3B
Adult onset Very high (median age at onset about 60; rare under age 30)

Contents

A.Classification codesB.Synonyms
1.History2.Causes
3.Genetics4.General epidemiology
5.Pathophysiology6.Symptoms
7.Signs8.Screening
9.Diagnosis10.Treatment
11.Prognosis12.Prevention
13.References

A. Classification codes

CodeName
C82Follicular lymphoma
C82.0Follicular lymphoma, grade 1 (small cleaved cells, few large cells)
C82.1Follicular lymphoma, grade 2 (small cleaved cells, many large cells)
C82.2Follicular lymphoma, grade 3 (large cells, large cleaved cells) — subdivided into 3A/3B
C82.3Follicular lymphoma, predominantly nodular type (small cleaved cells)
C82.4Follicular lymphoma, mixed small and large cells
C82.5Follicular lymphoma, large cell nodular
C82.6Cutaneous follicle center lymphoma
C82.8Other follicular lymphoma
C82.9Follicular lymphoma, unspecified

B. Synonyms

Follicular non-Hodgkin lymphoma, Brill-Symmers disease (obsolete term), nodular lymphocytic lymphoma (obsolete term), follicular centrocytic-centroblastic lymphoma. Grades 1 and 2 are grouped together as "low-grade follicular lymphoma," grade 3A is borderline, and grade 3B shows biological behavior comparable to diffuse large B-cell lymphoma (DLBCL).


1. History

The clinical entity of follicular lymphoma first became known in 1925 when Brill, Baehr, and Rosenthal described an unusual lymph node hyperplastic disease that preserved follicular architecture ("Brill-Symmers disease"). Symmers subsequently reported similar cases, and the name "Brill-Symmers disease" was used for some time. When Rappaport proposed a lymphoma classification system in 1956, lymphomas with a follicular pattern became established as an independent subtype, and the name "nodular poorly differentiated lymphocytic lymphoma" was used.

With the introduction of the Lukes-Collins classification and the Working Formulation in the 1970s–80s, the concept of "follicular centrocytic-centroblastic lymphoma" became established. During this period it was recognized that the natural course of follicular lymphoma, like that of other low-grade lymphomas, shows indolent progression over years to decades, yet it is difficult to cure with conventional treatment.

In a landmark discovery in 1984, the t(14;18)(q32;q21) chromosomal translocation was identified in about 85-90% of follicular lymphomas, and it was shown that this translocation places the BCL2 gene near the immunoglobulin heavy chain (IGH) promoter, inducing BCL2 overexpression. Resistance to apoptosis due to BCL2 overexpression became established as the key mechanism explaining the characteristic indolent cell accumulation of follicular lymphoma.

The clinical introduction of rituximab in 1997 revolutionized the treatment of follicular lymphoma. Rituximab, a monoclonal antibody targeting CD20, showed excellent efficacy alone or in combination in follicular lymphoma, and rituximab + chemotherapy (R-CVP, R-CHOP, R-bendamustine) became the standard treatment. Subsequently, the PRIMA study (2011) demonstrated that rituximab maintenance prolongs progression-free survival. In 2021, tazemetostat received FDA approval for EZH2-mutant follicular lymphoma, opening the era of epigenome-targeted therapy, and bispecific antibodies (mosunetuzumab, epcoritamab) showed high response rates in relapsed/refractory follicular lymphoma and were approved in 2022-2024.

2. Causes

t(14;18) translocation: The fundamental cause of follicular lymphoma is the t(14;18)(q32;q21) chromosomal translocation arising in germinal center B cells. This translocation moves the BCL2 gene near the enhancer of the IgH gene, inducing constitutive overexpression of the BCL2 protein. BCL2 is an anti-apoptotic protein that inhibits apoptosis by stabilizing the outer mitochondrial membrane.

Occupational and environmental factors: Exposure to herbicides (especially 2,4-D and the phenoxy acid class), organic solvents, and pesticides is reported as a risk factor for NHL in general. There are epidemiological studies showing that insecticide and fungicide exposure is also associated with NHL, including follicular lymphoma.

Immune status: The risk of NHL, including FL, increases with immunodeficiency (HIV infection, after organ transplantation) and autoimmune diseases. However, FL has a somewhat weaker association with immunodeficiency than other NHLs.

Genetic predisposition: A family history of FL increases the risk about 2-3-fold, and studies suggest that specific HLA variants such as HLA-DRB1 and HLA-DQA1 are associated with susceptibility. The t(14;18) translocation is also found at low frequency in the blood of healthy individuals, suggesting that this translocation alone is not sufficient for FL development and that additional molecular changes are required.

3. Genetics

t(14;18)(q32;q21)/BCL2-IGH: The characteristic translocation found in about 85-90% of follicular lymphomas. Constitutive overexpression of the BCL2 protein suppresses apoptosis, and germinal center B cells accumulate slowly. BCL2 overexpression is the molecular target of venetoclax (a BCL2 inhibitor).

EZH2 mutations: EZH2 Y641 activating mutations are found in about 20-25% of follicular lymphomas (GCB subtype). EZH2 silences tumor suppressor genes through histone H3K27 methylation (H3K27me3). Tazemetostat is an EZH2 inhibitor whose clinical efficacy has been demonstrated in EZH2-mutant FL (ORR 69%, FDA approval in 2021).

CREBBP/EP300 mutations: CREBBP (CBP) mutations are found in about 60-70% of FL and EP300 mutations in 30-40%. These are histone acetyltransferases (HATs), and when mutated they contribute to immune evasion, including reduced MHC II expression.

BCL6 rearrangement: BCL6 rearrangement is found in about 15-20% of FL and is more frequent particularly in grade 3A-3B FL. BCL6 is a transcription factor essential for the differentiation of germinal center B cells.

Changes associated with histologic transformation: When FL transforms to DLBCL, MYC amplification, CDKN2A/B loss, TP53 mutations, and acquisition of BCL6 rearrangement are frequently observed. DLBCL transformed from FL has a worse prognosis than de novo DLBCL.

FLIPI (Follicular Lymphoma International Prognostic Index): Five factors—elevated LDH, Ann Arbor stage III-IV, 5 or more nodal sites, age 60 or older, and hemoglobin <12 g/dL—classify patients into low-risk (0-1), intermediate-risk (2), and high-risk (3-5) groups. FLIPI-2 is an improved version that includes beta-2 microglobulin. m7-FLIPI (molecular FLIPI) is a high-risk prediction tool that includes the mutation status of EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11.

4. General epidemiology

Follicular lymphoma accounts for about 20-25% of all non-Hodgkin lymphomas (NHL) and is the most common indolent NHL in Western countries. About 15,000-20,000 people are newly diagnosed each year in the United States.

Age and sex: The median age at onset is about 60-65 years, and it is rare under age 40. The sex difference is small, but in Western countries it is slightly more common in women. Pediatric-type follicular lymphoma is rare and shows molecular characteristics different from the adult form.

Epidemiology in Korea: The incidence of FL in Asians is lower than in Western populations, and its proportion of all NHL is also about half that in Western countries. In Korean lymphoma registry studies (Korean Lymphoma Study Group), FL accounts for about 10-15% of all NHL, and DLBCL is the most common subtype. This difference is presumed to be related to ethnic differences in the frequency of the t(14;18) translocation and to environmental factors.

Natural course: Most cases (about 80%) are found at an advanced stage (stage III-IV) at diagnosis. A "watch and wait" strategy, in which the disease follows an indolent course for years without treatment, is applied in low-burden patients who do not need treatment. Spontaneous regression occurs rarely. Median survival was formerly 8-10 years but has been extended to 15-20 years or more in the rituximab era.

Histologic transformation: The rate at which indolent FL transforms to aggressive DLBCL is about 2-3% per year, with a cumulative risk of about 10-20% at 10 years. Transformation brings rapid clinical deterioration and a poor prognosis.

5. Pathophysiology

Stage 1: acquisition of the t(14;18) translocation. The t(14;18) translocation arises from RAG enzyme errors during V(D)J rearrangement in germinal center B cells. Because t(14;18)-positive B cells are detected at low frequency by PCR even in the peripheral blood of healthy individuals, this translocation alone is not sufficient for FL development.

Stage 2: BCL2 overexpression → resistance to apoptosis. BCL2 overexpression neutralizes pro-apoptotic proteins such as BAX and BAK, prolonging the lifespan of germinal center B cells. Normally, B cells not selected in the germinal center reaction undergo apoptosis, but BCL2-overexpressing cells survive and accumulate.

Stage 3: accumulation of additional molecular changes. Mutations in CREBBP/EP300, KMT2D, ARID1A, EZH2, TNFRSF14, and others are acquired sequentially and determine the phenotype of FL. These are involved in epigenetic regulation, immune signaling, and B-cell differentiation. Loss of TNFRSF14 (HVEM) affects immune regulation within the tumor microenvironment.

Stage 4: indolent accumulation → histologic transformation. Slow cell accumulation continues for years, and when high-risk changes such as MYC amplification, TP53 mutations, CDKN2A/B loss, and additional BCL6 rearrangement are added, histologic transformation to DLBCL occurs. Transformation can be promoted by EBV infection, radiation exposure, or immunosuppression.

Role of the tumor microenvironment (TME): The TME of FL plays a decisive role in tumor outcomes. T follicular helper cells (Tfh) support tumor cell survival, and immunosuppressive regulatory T cells (Treg), M2 macrophages, and the CXCL13-CXCR5 axis promote immune evasion and progression of FL. Studies suggest that TIM1 (HAVCR1)-positive B cells and PD-1-high Tfh are associated with a favorable-prognosis TME.

6. Symptoms

Painless lymphadenopathy: The most common presenting symptom; most patients present with painless lymphadenopathy that enlarges slowly over months or years. It commonly occurs simultaneously at multiple sites, such as the neck, axilla, and groin.

B symptoms (occurring in about 20-30%): B symptoms are less frequent than in Hodgkin lymphoma, but fever, night sweats, and weight loss may appear. The presence of B symptoms is associated with higher FLIPI scores and a poor prognosis.

Abdominal symptoms: Involvement of mesenteric or retroperitoneal lymph nodes causes abdominal discomfort, early satiety, decreased appetite, and abdominal pain. Left upper abdominal fullness and pain due to splenomegaly are also common.

Gastrointestinal symptoms: Gastrointestinal FL mainly involves the small intestine and can cause abdominal pain, diarrhea, and malabsorption symptoms (duodenal FL is classified as a separate entity). Bowel obstruction occurs rarely.

Asymptomatic (patients suitable for watch and wait): In some patients, lymphadenopathy is found on incidental imaging, or FL is diagnosed from lymphocytosis, but treatment may not be needed for months. Patients who do not meet the GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria are managed with a watch-and-wait strategy.

7. Signs

Multiple lymphadenopathy: Physical examination reveals painless, rubbery lymphadenopathy at multiple sites. Splenomegaly is observed in about 40-50% of patients.

Laboratory findings:

FLIPI score calculation:

FactorAdverse (1 point)
Ann Arbor stageIII-IV
Serum LDHAbove upper limit of normal
Age≥60 years
Nodal sites involved≥5 sites
Hemoglobin<12 g/dL

Low-risk group (0-1 points): 5-year survival 90%; high-risk group (3-5 points): 5-year survival 53%

8. Screening

There is no general population screening for follicular lymphoma. Follow-up of already diagnosed patients is key.

Surveillance during watch and wait: Patients with low tumor burden FL who do not meet the GELF criteria are followed with clinical evaluation and blood tests every 3 months without starting treatment. Surveillance for early detection of signs of histologic transformation—rapid increase in lymph node size, onset of B symptoms, LDH elevation—is important.

Post-treatment surveillance: Clinical evaluation every 3-6 months after complete remission. CT is performed when symptoms appear or relapse is suspected. PET-CT is not recommended for routine surveillance (due to radiation exposure and false positives). ctDNA (circulating tumor DNA) monitoring is being studied as a tool for early detection of relapse, and a growing number of studies show that patient-specific PCR or digital PCR using the BCL2-IGH rearrangement predicts relapse months ahead of imaging.

9. Diagnosis

Tissue biopsy: Excisional biopsy or core needle biopsy is mandatory. Sufficient tissue is needed to confirm the follicular pattern and determine the grade.

Pathological diagnostic criteria: follicular architecture (>75% follicular pattern); grade determined by the ratio of centrocytes (small cleaved cells) to centroblasts (large cells). Grade 1: 0-5 centroblasts/HPF, Grade 2: 6-15/HPF, Grade 3A: >15/HPF + residual centrocytes, Grade 3B: >15/HPF + solid sheets of centroblasts.

Immunohistochemistry (IHC):

Molecular and cytogenetic testing:

Staging: PET-CT (recommended for initial staging) or CT (chest/abdomen/pelvis). Bone marrow biopsy (to confirm stage Ⅲ-Ⅳ; may be omitted if bone marrow involvement is clear on PET-CT). FLIPI/FLIPI-2 score calculation.

10. Treatment

Low-burden FL (GELF criteria not met) — watch and wait

GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria: treatment is started if any one of the following is present—tumor diameter ≥7 cm, 3 or more lymph nodes ≥3 cm, B symptoms, splenomegaly, pleural effusion/ascites, cytopenias, or a leukemic phase (≥5,000/μL lymphoma cells). If these criteria are not met, a watch-and-wait strategy is applied. The median time to treatment initiation in the watch-and-wait group is about 2-3 years, and about 20-25% of patients do not need treatment for 5 years.

FL requiring treatment (first-line treatment)

Immunochemotherapy:

Rituximab maintenance: when complete/partial remission is achieved after first-line immunochemotherapy, rituximab is maintained for 2 years (once every 2 months). The PRIMA study demonstrated a significant benefit, with 3-year progression-free survival of 75% vs 58% (rituximab maintenance vs observation).

Tazemetostat: FDA-approved (2020) for relapsed/refractory EZH2-mutant FL after 2 or more prior treatments. Indication expanded to EZH2 wild-type FL as well. Single-agent ORR: 69% in the EZH2-mutant group, 35% in the wild-type group.

Bispecific antibodies:

PI3K inhibitors: idelalisib, copanlisib, umbralisib. ORR 40-60% in relapsed/refractory FL. Caution for immune-mediated toxicity (pneumonitis, colitis, hepatotoxicity).

CAR-T cell therapy: in relapsed/refractory FL, CD19-targeted CAR-T (axicabtagene ciloleucel, axi-cel) is under investigation in FL and shows promising response rates in double-refractory FL.

lenalidomide+rituximab (R2): an effective chemotherapy-free strategy in relapsed/refractory FL. Efficacy also demonstrated as maintenance therapy in the MAGNIFY study.

11. Prognosis

Follicular lymphoma follows a chronic indolent course that is difficult to cure with current treatment, but with median survival extended to 15-20 years or more, it represents the paradigm of a 'living with cancer' disease.

FLIPI risk group10-year survivalNotes
Low risk (0-1 points)About 71%Data from before the rituximab era
Intermediate risk (2 points)About 51%
High risk (3-5 points)About 36%

With improved overall survival since the introduction of rituximab, there are also reports that 10-year survival in the low-risk group reaches over 90%. POD24 (progression or death within 24 months of starting treatment) is recognized as the most important prognostic indicator in FL. When POD24 occurs, 5-year survival falls to about 50%. EZH2-mutant FL responds better to EZH2-targeted therapy than FL without this mutation. The risk of POD24 is significantly increased in the m7-FLIPI high-risk group.

12. Prevention

There is no specific prevention for follicular lymphoma. The following general cancer prevention principles and risk factor management may help.

Reducing environmental and occupational exposure: Minimize occupational exposure to herbicides, pesticides, and organic solvents. Use of personal protective equipment and exposure monitoring are recommended for agricultural workers. There is epidemiological evidence that these measures contribute to reducing the risk of NHL in general.

Maintaining immune function: Prevention and early treatment of HIV infection, minimizing immunosuppression. Appropriate treatment of autoimmune diseases may lower the risk of lymphoma arising from immune dysregulation.

Preventing histologic transformation (early treatment decisions in indolent FL): Early detection of signs of histologic transformation during watch and wait (rapid LDH rise, rapid lymph node enlargement, new onset of B symptoms) with prompt rebiopsy and initiation of treatment may improve prognosis after transformation. Confirming an adequate response to standard chemoimmunotherapy and adherence to maintenance therapy are important for maintaining long-term remission.


13. References

  1. Tsujimoto Y, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706):1440-1443.
  2. Marcus R, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344.
  3. Salles G, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA). Lancet. 2011;377(9759):42-51.
  4. Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433-1442.
  5. Luminari S, et al. Overall survival is not improved by the use of rituximab maintenance in patients with follicular lymphoma who receive a rituximab-containing induction regimen. J Clin Oncol. 2018;36(19):1905-1913.
  6. Schmatz AI, et al. Primary follicular lymphoma of the duodenum. J Clin Oncol. 2011;29(11):e305-e308.
  7. Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death. J Clin Oncol. 2015;33(23):2516-2522.
  8. Korean Society of Hematology. Clinical Practice Guideline for Follicular Lymphoma. 2023.
  9. NCCN Clinical Practice Guidelines: B-Cell Lymphomas. Version 4.2025.
  10. Korean Lymphoma Study Group. Clinical features and treatment outcomes of follicular lymphoma in Korea. Blood Res. 2022.